November 21, 2016 11:03 ET
TORONTO, ONTARIO--(Marketwired - Nov. 21, 2016) -
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES
PharmaCan Capital Corp. doing business as Cronos Group ("Cronos Group" or the "Company") (TSX VENTURE:MJN) announces it has granted options to a consultant to the Company to subscribe to 182,000 common shares of the Company, the whole in accordance with the Company's stock option plan. The options are exercisable at a price of $1.84 per common share, which was the closing price of the Company's common shares on the TSX-V on November 18, 2016. The options shall expire at the earlier of 180 days of the death, disability or incapacity of the holder or five years after the date of issue. The grant of options is subject to the Company receiving all necessary and appropriate regulatory consents and approvals, if any, and to the Company's stock option plan.
About Cronos Group:
Cronos Group, is a geographically diversified and vertically integrated cannabis company that operates two wholly-owned Licensed Producers ("LPs") regulated within Health Canada's Access to Cannabis for Medical Purposes Regulations (the "ACMPR") and holds a portfolio of minority investments in other Licensed Producers and ACMPR applicants. The company's flagship LPs, Peace Naturals Project Inc. (Ontario), and In The Zone Produce Ltd. (British Columbia) are collectively situated on over 125 acres of agricultural land and are currently licensed to produce 2,600 kg of cannabis on an annual basis. The Company also holds minority equity positions in Licensed Producers Whistler Medical Marijuana, Hydropothecary, and Abcann Medicinals. With interest in five Licensed Producers and two LP applicants, Cronos Group is focused on building an iconic brand portfolio, providing patients with compassionate and personalized care, and creating value for our shareholders.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
PharmaCan Capital Corp.Investor & Media RelationsMichael Krestell(416) 603-7381 EXT #email@example.com
See all RSS Newsfeeds